Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Gritstone Oncology Inc (GRTS) USD0.0001

Sell:$6.29 Buy:$6.30 Change: $0.04 (0.63%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Change: $0.04 (0.63%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Change: $0.04 (0.63%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gritstone Oncology, Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE, which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA, and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens.

Contact details

5858 Horton St Ste 210
United States
+1 (510) 8716100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$245.20 million
Shares in issue:
37.26 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Elaine Jones
    Chairman of the Board
  • Andrew Allen
    President, Chief Executive Officer, Director
  • Jean-Marc Bellemin
    Chief Financial Officer, Executive Vice President
  • Roman Yelensky
    Executive Vice President, Chief Technology Officer
  • Karin Jooss
    Executive Vice President - Research, Chief Scientific Officer
  • Matthew Hawryluk
    Executive Vice President, Chief Business Officer
  • Erin Jones
    Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance
  • Raphael Rousseau
    Executive Vice President, Chief Medical Officer
  • Vijay Yabannavar
    Executive Vice President, Manufacturing and Technical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.